Aspy Logo.jpg

Precision Targeted Therapies for Cancer

A first-in-class cancer treatment utilizing antibody conjugates with tumor specific activation that results in unprecedented cancer specific killing. 

Aspyrian Therapeutics, Inc., has initiated a phase I study, RM-1929/101, to treat recurrent Head and Neck Cancer Patients. For information about the trial please visit the clinical webpage or Clinicaltrials.gov.

For enrollment consideration please contact us directly.